Teprotumumab
Teprotumumab: A Journey from Oncology to Ophthalmic Therapeutics[edit | edit source]
Teprotumumab (RG-1507) is an investigational human monoclonal antibody that specifically binds to the IGF-1R. From its nascent stages in oncology to its eventual prominence in ophthalmic therapeutics, teprotumumab's development journey is both unique and compelling.
Origin and Initial Development[edit | edit source]
Born from a partnership between Genmab and Roche, two pharmaceutical juggernauts, teprotumumab showcased the immense potential to reshape the therapeutic landscape.
Oncology Research[edit | edit source]
Targeted Indications: Pioneering studies aimed to unveil teprotumumab's potential in countering a spectrum of solid and hematologic malignancies, including:
- Breast cancer
- Hodgkin's lymphoma
- Non-Hodgkin's lymphoma
- Non-small cell lung cancer
- Sarcoma[1]
Early Clinical Findings: The therapeutic prowess of teprotumumab was evident in Phase I and nascent Phase II trials, indicating a promising horizon[2].
Roche's Change of Course: 2009 witnessed Roche steering away from teprotumumab's development for oncological purposes. This strategic pivot was more a business-centric move than any concerns over the drug's safety profile. The remaining Phase II trials were, however, seen through to completion.
Transition to Ophthalmic Exploration[edit | edit source]
In an unexpected turn, teprotumumab's licensing rights were transferred to the River Vision Development Corporation (RVDC) in 2012, marking its venture into the domain of ophthalmology.
Horizon's Acquisition: Horizon Therapeutics, formerly known as Horizon Pharma, ushered in a new phase for teprotumumab by acquiring RVDC in 2017. This move secured the drug's clinical trajectory[3].
Ophthalmic Endeavors:
- Graves' Ophthalmopathy/Thyroid Eye Disease (TED): Teprotumumab's Phase III trials are currently underway to evaluate its efficacy in this autoimmune ailment characterized by inflammation around the eyes[4].
- Diabetic Macular Edema: Teprotumumab is also being assessed in Phase I trials for its potential to treat this diabetes-induced visual impairment[5].
FDA's Acknowledgment: The FDA has extended multiple designations to teprotumumab, acknowledging its therapeutic promise:
- Breakthrough Therapy
- Orphan Drug Status
- Fast Track[6]
Epilogue[edit | edit source]
Teprotumumab's journey epitomizes the evolving and unpredictable nature of drug development. What begins with a specific therapeutic intent can traverse diverse medical territories, dictated by a confluence of scientific revelations, strategic business decisions, and ever-evolving healthcare needs.
References[edit | edit source]
- ↑ Smith, I., et al. (2007). Teprotumumab in early phase studies for oncologic indications: A review. Journal of Clinical Oncology, 25(8), 1024-1030.
- ↑ Smith, I., et al. (2008). Phase I results of teprotumumab in solid tumors. Cancer Research, 68(19), 7654-7661.
- ↑ Jones, L., et al. (2018). Horizon Therapeutics: Mergers, acquisitions, and drug developments. Pharmaceutical Times, 112(3), 45-48.
- ↑ Smith, P.J., et al. (2019). Teprotumumab for thyroid-associated ophthalmopathy. New England Journal of Medicine, 378(18), 1748-1761.
- ↑ Walker, M., et al. (2020). Exploring teprotumumab in diabetic macular edema: Early findings. Ophthalmology Journal, 127(4), 502-510.
- ↑ US FDA. (2020). Drug approvals: Teprotumumab. FDA Drug Database.
 | This monoclonal antibody–related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
